Solid Biosciences Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $8.1M | $13.6M | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $140.3M | $96.4M | $76.6M | $78.4M | $58.7M | $64.9M | $94.7M |
| SG&A Expense | — | $38.9M | $33.3M | $27.8M | $28.9M | $27.1M | $21.6M | $24.6M |
| Operating Income | — | $-179.2M | $-129.7M | $-104.3M | $-106.5M | $-72.3M | $-88.4M | $-119.3M |
| Operating Margin | — | — | — | — | -1,315.2% | -530.5% | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-174.2M | $-124.6M | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | — | $-174.3M | $-124.7M | $-96.0M | $-86.0M | $-72.2M | $-88.3M | $-117.2M |
| Net Margin | — | — | — | — | -1,062.3% | -530.0% | — | — |
| EPS (Basic) | — | $-1.99 | $-1.53 | $-1.21 | $-1.26 | $-1.27 | $-1.59 | $-0.18 |
| EPS (Diluted) | — | $-1.99 | $-1.53 | $-1.21 | $-1.26 | $-1.27 | $-1.59 | $-0.18 |
| Shares Outstanding (Basic) | 98.4M | 87.5M | 81.6M | 79.5M | 68.1M | 56.9M | 55.4M | 735.8M |
| Shares Outstanding (Diluted) | 98.4M | 87.5M | 81.6M | 79.5M | 68.1M | 56.9M | 55.4M | 735.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |